Premium
B and T Cell Epitope‐Based Peptides Predicted from Evolutionarily Conserved and Whole Protein Sequences of Ebola Virus as Vaccine Targets
Author(s) -
Yasmin T.,
Nabi A. H. M. Nurun
Publication year - 2016
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/sji.12425
Subject(s) - epitope , biology , human leukocyte antigen , mhc class i , genetics , allele , virology , major histocompatibility complex , phylogenetic tree , mhc class ii , computational biology , antigen , gene
Ebola virus ( EBV ) has become a serious threat to public health. Different approaches were applied to predict continuous and discontinuous B cell epitopes as well as T cell epitopes from the sequence‐based and available three‐dimensional structural analyses of each protein of EBV . Peptides ‘ 79 VPSATKRWGFRSGVPP 94 ’ from GP 1 and ‘ 515 LHYWTTQDEGAAIGLA 530 ’ from GP 2 of Ebola were found to be the consensus peptidic sequences predicted as linear B cell epitope of which the latter contains a region 519 TTQDEG 524 that fulfilled all the criteria of accessibility, hydrophilicity, flexibility and beta turn region for becoming an ideal B cell epitope. Different nonamers as T cell epitopes were obtained that interacted with different numbers of MHC class I and class II alleles with a binding affinity of <100 n m . Interestingly, these alleles also bound to the MHC class I alleles mostly prevalent in African and South Asian regions. Of these, ‘ LANETTQAL ’ and ‘ FLYDRLAST ’ nonamers were predicted to be the most potent T cell epitopes and they, respectively, interacted with eight and twelve class I alleles that covered 63.79% and 54.16% of world population, respectively. These nonamers were found to be the core sequences of 15mer peptides that interacted with the most common class II allele, HLA ‐ DRB 1*01:01. They were further validated for their binding to specific class I alleles using docking technique. Thus, these predicted epitopes may be used as vaccine targets against EBV and can be validated in model hosts to verify their efficacy as vaccine.